Aimovig

What Is Aimovig?

Aimovig (erenumab-aooe) Injection is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults.

What Are Side Effects of Aimovig?

Common side effects of Aimovig include:

• injection site reactions (pain or redness),
• constipation, and
• muscle spasms or
• cramps

Dosage for Aimovig

The recommended dosage of Aimovig is 70 mg once monthly; some patients may benefit from a dosage of 140 mg once monthly, which is administered as two consecutive subcutaneous injections of 70 mg each.

What Drugs, Substances, or Supplements Interact with Aimovig?

Aimovig may interact with other drugs. Tell your doctor all medications and supplements you use.

Aimovig During Pregnancy and Breastfeeding

Tell your doctor if you are pregnant or plan to become pregnant before using Aimovig; it is unknown how it could affect a fetus. It is unknown if Aimovig passes into breast milk. Consult your doctor before breastfeeding.

Additional Information

Our Aimovig (erenumab-aooe) Injection, for Subcutaneous Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

 

Aimovig Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Common side effects may include:

• constipation; or
• pain, swelling, or redness where the medicine was injected.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Aimovig (Erenumab-aooe Injection, for Subcutaneous Use)

 

Aimovig Professional Information

SIDE EFFECTS

The following serious adverse reactions are described below and elsewhere in the labeling:

• Hypersensitivity Reactions [see WARNINGS AND PRECAUTIONS]
• Constipation with Serious Complications [see WARNINGS AND PRECAUTIONS]
• Hypertension [see WARNINGS AND PRECAUTIONS]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety of AIMOVIG has been evaluated in 2537 patients with migraine who received at least one dose of AIMOVIG, representing 2310 patient-years of exposure. Of these, 2057 patients were exposed to 70 mg or 140 mg once monthly for at least 6 months, 1198 patients were exposed for at least 12 months, and 287 patients were exposed for at least 18 months.

In placebo-controlled clinical studies (Studies 1, 2, and 3) of 2184 patients, 787 patients received at least one dose of AIMOVIG 70 mg once monthly, 507 patients received at least one dose of AIMOVIG 140 mg once monthly, and 890 patients received placebo during 3 months or 6 months of double-blind treatment [see Clinical Studies]. Approximately 84% were female, 91% were white, and the mean age was 42 years at study entry.

The most common adverse reactions (incidence ≥ 3% and more often than placebo) in the migraine studies were injection site reactions and constipation. Table 1 summarizes the adverse reactions that occurred during the first 3 months in the migraine studies (Studies 1, 2, and 3).

Table 1: Adverse Reactions Occurring with an Incidence of at Least 2% for Either Dose of AIMOVIG and at Least 2% Greater than Placebo During the First 3 Months in Studies 1, 2, and 3

Adverse Reaction	AIMOVIG 70 mg Once Monthly N = 787 %	AIMOVIG 140 mg Once Monthly N = 507 %	Placebo N = 890 %
Injection site reactionsa,b	6	5	3
Constipation	1	3	1
Cramps, muscle spasms	<1	2	<1
aInjection site reactions include multiple adverse reactions related terms, such as injection site pain and injection site erythema. b The rate of injection site reactions reported in Table 1 is with the prefilled syringe.

In Studies 1, 2, and 3, 1.3% of patients treated with AIMOVIG discontinued double-blind treatment because of adverse events. The most frequent injection site reactions were injection site pain, injection site erythema, and injection site pruritus.

Immunogenicity

As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation, including neutralizing antibodies, is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to erenumab-aooe in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.

The immunogenicity of AIMOVIG has been evaluated using an immunoassay for the detection of binding anti-erenumab-aooe antibodies. For patients whose sera tested positive in the screening immunoassay, an in vitro biological assay was performed to detect neutralizing antibodies.

In controlled studies with AIMOVIG, the incidence of anti-erenumab-aooe antibody development was 6.2% (48/778) in patients receiving AIMOVIG 70 mg once monthly (2 of whom had in vitro neutralizing activity) and 2.6% (13/504) in patients receiving AIMOVIG 140 mg once monthly (none of whom had in vitro neutralizing activity). The neutralizing anti-erenumab-aooe antibody positive rate may be underestimated because of limitations of the assay. Although these data do not demonstrate an impact of anti-erenumab-aooe antibody development on the efficacy or safety of AIMOVIG in these patients, the available data are too limited to make definitive conclusions.

Postmarketing Experience

The following adverse reactions have been identified during postapproval use of AIMOVIG. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune System Disorders: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis [see WARNINGS AND PRECAUTIONS].

Gastrointestinal Disorders: Constipation with serious complications [see WARNINGS AND PRECAUTIONS], oral mucosal ulceration.

Skin and Subcutaneous Tissue Disorders: Rash, alopecia.

Vascular Disorders: Hypertension [see WARNINGS AND PRECAUTIONS].

DRUG INTERACTIONS

No Information Provided

Read the entire FDA prescribing information for Aimovig (Erenumab-aooe Injection, for Subcutaneous Use)